As expected, Miap410 Ab treatments caused an initial drop in the erythrocyte count that returned to normal within 3 weeks (Supplemental Figure 5F), which is similar to the situation reported in human patients who had received CD47 Ab as a treatment for cancer (47). This evidence concerns the gene CD47 and cancer.